Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate
July 19, 2017 04:35 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 19, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the...